GALT · Biotechnology
Galectin Therapeutics Inc.
Clinical-stage biopharma developing belapectin for MASH cirrhosis.
- Rating
- Price
- $3.64
- Price target
- $1.70
- Implied return
- -53%
- Market value
- $367M
- Next results
- November 2026
GALT$1.70-53%
Our view
Vishal Bhargava, CFA · updated Oct 9, 2026Target $1.70Implied return -53%Bear to bull $0.00 to $6.47
Belapectin missed its Phase 2b/3 primary endpoint on the full analysis set, and the positive reading is per-protocol. A $367M market value rests on that subgroup result and a Phase 3 nobody has yet funded.
What could prove us wrong
- Phase 3 fails or repeats the NAVIGATE result
- A funding gap before Phase 3: $13.3M of cash against a $110M budget, with $30M of notes due 30 Jun 2027
- Dilution: a partner or about $55M of equity (+19% shares) is likely needed within roughly 12 months
Ask the analyst about GALT
Answers come from Penmark’s GALT research and the company’s filings, with a source for each claim. Change an assumption and the assistant reruns the report’s valuation.